Signaling Pathway
Important Notice: For research use only. We do not sell to patients.
Not your Region? View all Distributors
| Discription | GLPG0634 is an orally-available, selective inhibitor of JAK1 (Janus kinase 1) being developed by Galapagos for the treatment of rheumatoid arthritis and potentially other inflammatory diseases. | ||
|---|---|---|---|
| Targets |
|
| Catalog Num | A13162 |
|---|---|
| Formula | C23H18N6O2 |
| Molecular Weight | 410.15 |
| CAS Number | 1206101-20-3 |
| SMILES | c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)OCc5ccc(nc5)C#N |
| Synonyms | GLPG 0634, GLPG-0634 |
| Storage | Store lyophilized at -20ºC, keep desiccated. |
| In vitro | DMSO | 0.09 mg/mL (0.22 mM) | |
| Water | Insoluble | ||
| Ethanol | Insoluble | ||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.1 mM | 24.38 mL | 121.91 mL | 243.81 mL |
| 0.5 mM | 4.88 mL | 24.38 mL | 48.76 mL |
| 1 mM | 2.44 mL | 12.19 mL | 24.38 mL |
| 5 mM | 0.49 mL | 2.44 mL | 4.88 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
